ITOG Quarterly Update Newsletter
July 2019

Manisha Shah, MD
ITOG Chair
Dear ITOG Friends!

Wow, what an incredibly welcoming, well organized and productive ITOG Annual Meeting it was in NYC in early May 2019!! Please join me in thanking our host and host teams at the MSKCC and Cornell for ‘one of the very best’ meetings! I would like to thank all of you who were able to join in person or in spirit to make those 3 days joyful and memorable! Finally, let me express deep gratitude on behalf of all of us to Donna LeBeau, Kimberly Caplea and Rosie Sherman who filled our Saturday evening with so much inspiration and gave meaning to our meeting and our mission at the ITOG.

I am honored to be supported by very dedicated and talented Board of Directors and our hard working administrative associate Extraordinaire—Ms. Judy Dallas. With such an ‘awesome’ team, I look forward to starting the second year of my journey as your Chair and commit to work hard to make you proud! I would like to finish this note by reminding ourselves ‘Don’t forget to stop and smell roses’ this summer!

www.ITOG.org

ITOG Active Clinical Trials

**ACCRU/ITOG 1504 Combination Immunotherapy with Multikinase Inhibitor (MKI) in Progressive, Radiodine-resistant Differentiated Thyroid Cancers**
Accrual Status: Accruing
Accrual Goal: 60
Current Accrual: 49 (Cohort 1 - 30 Cohort 2 - 19)
Sponsors: Eisai/Merck
Coordinating organization: ACCRU
Principal Investigator (PI): Bryan Haugen, MD at University of Colorado Medical Center
Principal Investigator Email: Bryan.Haugen@ucdenver.edu
Co-PI: Lori Wirth, MD
Publication/Presentation Status: Pending

***Status Change March 26, 2019 - Cohort 1 is permanently closed to patient accrual per protocol as of March 26, 2019.

Selumetinib plus RAI for RAI-Avid Thyroid Cancers
Accrual Status: Accruing
Accrual Goal: 60
Current Accrual: 52
Sponsor: Astrazeneca
Coordinating organization: ACCRU
Principal Investigator Email: hoa@mskcc.org
Co-PI: Mabel Ryder, MD
Publication/Presentation Status: Pending

Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Accrual Status: Accruing
Sponsor: Loxo-Oncology
Coordinating organization: LOXO-Oncology
Leader at ITOG: Lori Wirth and ITOG protocol-specific steering committee
Leader Email: lirth@mgh.harvard.edu
Publication Status: Pending
Presentations: ASCO Jun 2018, ATA Oct 2018
Phase II Study of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy

Accrual Status: Permanently closed
Accrual Goal: 25
Current Accrual: 25
Sponsors: CTEP/NCI, ITOG
Coordinating organization: ACCRU
Principal Investigator: Manisha Shah, MD at The Ohio State University
Principal Investigator Email: manisha.shah@osumc.edu
Co-PI: Maria Cabanillas, MD

Publication Status: Published Journal of Clinical Oncology - Oct 2017 JCO.2017.73.0226

--------------------------------

An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)

Accrual Status: Terminated
Sponsor: Eisai
Coordinating organization: Eisai
Leader at ITOG: Lori Wirth and ITOG protocol-specific steering committee
Leader Email: LWIRTH@mgh.harvard.edu
Publication/Presentation Status: Pending

--------------------------------

ALLIANCE A091302
Randomized Phase II Study of Sorafenib with or without Everolimus in Patients with Radioactive Iodine Refractory Hurtle Cell Thyroid Cancer (Pl- Dr. E. Sherman); Alliance study, but with disappointing accrual. Collaboration with ITOG with acknowledgement based on criteria of accrual at ITOG centers. Currently 26 patients accrued; target is 30-34 patients. University of Michigan and Ohio State have already opened the study. Mass General and Fox Chase Cancer Center are about to open.
Target Accrual goal: 30
Accrued to date: 30
Principal Investigator: Eric Sherman, MD Memorial-Sloan Kettering Cancer Center
Principal Investigator Email: shermane@mskcc.org

--------------------------------

ITOG Upcoming Trials

CTEP approved LOI #10240: Phase II Study of Cabozantinib in combination with Nivolumab and Ipiilimumab (CaboNivoIpi) in Patients with Radioiodine-refractory Differentiated Thyroid Cancer whose Cancer Progressed after 1 Prior VEGFR-Targeted Therapy

(Protocol in Development) Estimated date of activation July 15, 2019.
Principal Investigator: Bhavana Konda, MD
Principal Investigator Email: Bhavana.Konda@osumc.edu
The Ohio State University

OSU 17277: A Phase 1 Trial of concurrent Intensity Modulated Radiation Therapy (IMRT) and DABRAFENIB/TRAMETINIB IN BRAF MUTATED ANAPLASTIC OR POORLY DIFFERENTIATED THYROID CANCER

(In Development)
Principal Investigator: Manisah Shah, MD
Primary Investigator Email: Manisah.shah@osumc.edu
The Ohio State University

ITOG TOP NEWS
Save-the-Date

The ITOG 2020 Annual Meeting
Wednesday May 13, 2020—Friday May 15, 2020
Gustave Roussy Paris, France
Hosted by Sophie Leboulleux and Team

Wednesday
8:00 – 3:00 Board of Directors and Committee Meetings
3:00 – 5:00PM Business Meeting (ITOG Members Only)
5:00 – 7:00 Welcome Dinner for all attendees

Thursday
8:00 – 5:00 Scientific Meetings
Dinner on your own

Friday
8:00 – 5:00 Scientific Meetings
6:00 – 9:00 Dinner

(Please note this schedule is tentative and subject to change)

CALL FOR NOMINATIONS

ITOG BOARD OF DIRECTORS INTERNATIONAL MEMBER
Submit your Nomination Online July 1, 2019 - July 12, 2019

The International Thyroid Oncology Group (ITOG) strives to foster a climate of purposeful inclusion of all people. We value the diversity of racial, cultural identity, geographical, institutional, and medical specialty.

The ITOG Executive Committee, invites the general membership to nominate international members who are qualified and dedicated to the mission of this organization, to serve on the Board of Directors

To require a minimum of one (1) international member on the ITOG Board of Directors. This would require a nomination and election for one (1) seat for international member. The term on the Board will be 3 years. International Member is defined as any ITOG member at an institution outside of the United States.

If you are interested in nominating an International Member to serve on the ITOG Board of Directors by Friday July 12, 2019.

Please click here to use the Online Nomination Form

Current International Members, for reference only.

<table>
<thead>
<tr>
<th>Name</th>
<th>Specialty</th>
<th>Institution</th>
<th>Country</th>
<th>ITOG Current/Previous International BOD Members</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jaume Capdevila Castillón,</td>
<td>Medical Oncology</td>
<td>Vall D ‘Hebron University Hospital, Medical Oncology Service</td>
<td>Spain</td>
<td></td>
</tr>
<tr>
<td>MD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cosimo Durante, MD</td>
<td>Endocrinology</td>
<td>University of Rome, Sapienza</td>
<td>Italy</td>
<td></td>
</tr>
<tr>
<td>Rossella Elisei, MD</td>
<td>Endocrinology</td>
<td>Universita' degli Studi di Roma &quot;La Sapienza&quot;</td>
<td>Italy</td>
<td></td>
</tr>
<tr>
<td>Sebastiano Filetti, MD</td>
<td>Endocrinology</td>
<td>University of Milan and Fondazione IRCCS Ca’ Granda, Milan-Italy</td>
<td>Italy</td>
<td></td>
</tr>
<tr>
<td>Laura Fugazzola, MD</td>
<td>Endocrinology and Metabolism</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monika Krzyzanowska, MD</td>
<td>Medical Oncology</td>
<td>Princess Margaret Hospital</td>
<td>Canada</td>
<td></td>
</tr>
<tr>
<td>Sophie Leboulleux, MD</td>
<td>Endocrinology</td>
<td>Institut Gustave Roussy</td>
<td>France</td>
<td></td>
</tr>
<tr>
<td>Kate Newbold, MD</td>
<td>Endocrinology</td>
<td>The University of Sydney Royal North Shore Hospital</td>
<td>Australia</td>
<td></td>
</tr>
</tbody>
</table>
We are proud to announce the opening of the 2019 Request for Applications for The Robert F. Gagel ITOG Discovery Award.

The Robert F. Gagel ITOG Discovery Award for $100,000 will be granted over a two-year period, consisting of $50,000 per year. Applications must be devoted to a scientific proposal with direct and tangible translational implications toward developing novel or improved treatments for thyroid cancer. This may include any of the following:

1. Preclinical studies.
2. Mechanism-based correlative studies of thyroid cancer clinical trials.
3. Proposals for resources (registries, genomic databases that assist in the identification of subjects for ITOG-sponsored clinical trials.

The awardee will be expected to present a progress report to the ITOG membership at the Annual Meeting after one year, and at the completion of the project. Funding for the second year is contingent upon satisfactory progress after year one.

All ITOG members in good standing are eligible to apply. The proposal will be limited to three pages and is expected to provide background information and pilot data, hypotheses, specific aims, a research plan and facilities, and impact on or relevance to thyroid cancer treatment. A preliminary budget is required. No indirect funding will be provided.

Applications will be reviewed by ITOG’s Committee for Correlative Sciences Co-chaired by Dr. James Fagin and Dr. Alan Ho. The final funding decision will be made by the Board of Directors. Applicants will be notified of award by December 31, 2019, and funding will begin in January 2020 for 2 years.

All ITOG members in good standing are eligible to apply.

Of note, previous awardees have been Dr. Yariv Houvras (2016-2018) and Dr. Sareh Parangi (2018-2020)

Please see the attached Request for Application for details.

Proposals should be submitted via email with “Gagel Award” in subject line to judy.dallas@osumc.edu

Deadline for receipt of applications shall be September 1, 2019

Welcome Our New Members!
The ITOG 2019 Annual Meeting, was held May 3, 2019 - May 5, 2019 at the Zuckerman Auditorium Memorial Sloan Kettering Cancer Center. The meeting was hosted by David Pfister, Eric Sherman, Alan Ho, Michael Tuttle, Yariv Houvras and MSKCC Team. The overall attendee feedback indicated that the new meeting format was a success! 

Click here to see Post Meeting Survey Results
ITOG 2019 Annual Meeting Photos
ITOG 2019 Annual Meeting Photos_2

Congratulations to David Pfister and the MSKCC Team!
There is still time to submit your request!
Call for ITOG Committee Members
Terms May 2019 – April 2022
Click Here to Volunteer for ITOG Committees
> Basic Science and Correlative Science
> Clinical Protocols
> Finance
> Website and Communications
> Annual Meeting Planning Task Force

Call for Hosting 2021 ITOG Annual Meeting
Call for 2021 Annual Meeting Host Now Open
Click here to Volunteer to Host the 2021 ITOG Annual Meeting
Or email the Chair at Manisha.shah@osumc.edu or judy.dallas@osumc.edu

2019 National and International Meetings And Events

- 42nd Annual Meeting of the European Thyroid Association September 7 – 10, Budapest, Hungary
- NANETS Annual Symposium October 3-5, Boston, MA
- ThyCa 22nd International Conference October 18 – 20, Denver, CO
- ATA 89th Annual Meeting October 30-November 3, Chicago, IL
- Alliance 2019 Fall Group Meeting November 7 – 9, Rosemont, IL

Development News

ITOG Welcomes REACT Co-Founders to the 2019 Annual Meeting

Michelle LeBeau's mother Donna LeBeau (Center) and Sister Kimberly Caplea, (3rd from right) were recognized at the Annual Closing Dinner. We are most grateful to Michelle LeBeau's mother Donna LeBeau, and sister Kimberly Caplea, for choosing ITOG to carry on Michelle's legacy. In Donna's words, “ITOG is the preeminent organization that brings together the leaders in the field to develop better treatments for all types of thyroid cancer, including MTC.”

Michelle LeBeau started REACT (Research Education Action Cancer Thyroid) when diagnosed with medullary thyroid carcinoma (MTC) at the age of 30. REACT was a 501-(c)3 corporation. Michelle raised awareness and resources for MTC and invested grants to advance the treatment and understanding of the disease. Some of these grants were awarded to ITOG physicians. At the time of the merger, REACT had $295,000. ITOG will invest these resources consistent with its mission of catalyzing the cure for not just for MTC, but all types of thyroid cancer. Michelle succumbed to the disease in 2015.
Development

Donations to ITOG support our mission to catalyze a cure for thyroid cancer. Thyroid cancer has been relatively underfunded compared to other solid tumors. ITOG and its members have played a critical role in organizing the most sophisticated clinical trials to discover and characterize new drugs for thyroid cancer treatment. Your support will make a difference. Philanthropy is a key for ITOG to achieve success. Hundreds of individuals whose lives have been touched by thyroid cancer have contributed to our mission. Make your voice heard by donating today.

ITOG is a 501(c)(3) tax-exempt public charity. Donations are tax deductible.

Donate Today
Get Involved

Submit an Item to the ITOG Quarterly Update

All submissions must be relevant to the mission and Purpose of ITOG. Please take time to proof and edit submissions. Please keep in mind we may not use all submissions, but appreciate you sharing. We reserve the right to edit submissions for content and length. Please send to judy.dallas@osumc.edu

Submission Guidelines:

- No more than 150 words
- Include the name of author, job title, email and institution
- All submissions should be saved in MS Word
- Photos and artwork send as .jpg files.
- Recent publications
- Upcoming & recently completed presentations (within 90 days)
  - Organization, Date, Location, Title
- Open Positions for Employment in Your Division/Department
  - Position title, location, contact information